Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Gtpl9416
2. Isis396443
Molecular Weight | 7127 g/mol |
---|---|
Molecular Formula | C234H340N61O128P17S17 |
XLogP3 | -14.4 |
Hydrogen Bond Donor Count | 40 |
Hydrogen Bond Acceptor Count | 167 |
Rotatable Bond Count | 176 |
Exact Mass | 7124.2829700 g/mol |
Monoisotopic Mass | 7122.2762603 g/mol |
Topological Polar Surface Area | 2820 Ų |
Heavy Atom Count | 457 |
Formal Charge | 0 |
Complexity | 19100 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 72 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41707
Submission : 2025-03-28
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 71860-396
Start Marketing Date : 2016-12-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41707
Submission : 2025-03-28
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 23, 2025
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 23, 2025
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 10, 2024
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Promising Results For Higher Dose of Spinraza
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 10, 2024
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase IVProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2024
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Biomarker Data Support Potential Benefit of SPINRAZA in Infants
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 03, 2024
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Lantesens
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Russia registers domestic generic of Spinraza
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Lantesens
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 14, 2024
Details:
Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2024
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Reports Positive Topline Results For Higher Dose Of Nusinersen in SMA
Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
April 09, 2024
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Royalty Pharma
Deal Size: $1,125.0 million Upfront Cash: $500.0 million
Deal Type: Agreement September 01, 2023
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $1,125.0 million
Deal Type : Agreement
Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : $500.0 million
September 01, 2023
Details:
SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Biogen
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 27, 2023
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 27, 2023
Details:
SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Biogen
Deal Size: $51.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration April 01, 2023
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Biogen
Deal Size : $51.0 million
Deal Type : Collaboration
Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : $10.0 million
April 01, 2023
Details:
RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA (nusinersen) treatment following gene therapy was well-tolerated.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2022
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA (nusinersen) treatment following gene therapy was well-tolerated.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 15, 2022
Details:
The results from NURTURE, a study in infants treated in presymptomatic stage of SMA, demonstrate that early and sustained treatment with SPINRAZA for up to 5.7 years, helped participants to maintain and make progressive gains in motor function.
Lead Product(s): Nusinersen Sodium
Therapeutic Area: Genetic Disease Brand Name: Spinraza
Study Phase: Approved FDFProduct Type: Oligonucleotide
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 14, 2022
Lead Product(s) : Nusinersen Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Details : The results from NURTURE, a study in infants treated in presymptomatic stage of SMA, demonstrate that early and sustained treatment with SPINRAZA for up to 5.7 years, helped participants to maintain and make progressive gains in motor function.
Product Name : Spinraza
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
March 14, 2022
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Regulatory Info : USA
Registration Country : Greece
Brand Name :
Dosage Form : Solution For Injection
Dosage Strength : 12MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : USA
Registration Country : Greece
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
Packaging :
Regulatory Info : USA
Dosage : Solution For Injection
Dosage Strength : 12MG/5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Greece
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
20 Mar 2020
Reply
25 Jun 2019
Reply
28 Aug 2018
Reply
10 Dec 2018
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1944
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11
Patent Expiration Date : 2036-03-04
US Patent Number : 12013403
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1942
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-04
Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11
Patent Expiration Date : 2030-06-17
US Patent Number : 9717750
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1942
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-17
Patent Expiration Date : 2036-03-04
US Patent Number : 12013403
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1943
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-04
Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1941
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11
Patent Expiration Date : 2030-06-17
US Patent Number : 9717750
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-2094
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-17
Patent Expiration Date : 2036-03-04
US Patent Number : 12013403
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-1944
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-03-04
Patent Expiration Date : 2035-09-11
US Patent Number : 10436802
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-2093
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-09-11
Patent Expiration Date : 2030-06-17
US Patent Number : 9717750
Drug Substance Claim :
Drug Product Claim :
Application Number : 209531
Patent Use Code : U-2093
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-06-17
ABOUT THIS PAGE
59
PharmaCompass offers a list of Nusinersen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Nusinersen manufacturer or Nusinersen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nusinersen manufacturer or Nusinersen supplier.
PharmaCompass also assists you with knowing the Nusinersen API Price utilized in the formulation of products. Nusinersen API Price is not always fixed or binding as the Nusinersen Price is obtained through a variety of data sources. The Nusinersen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Nusinersen Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nusinersen Sodium, including repackagers and relabelers. The FDA regulates Nusinersen Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nusinersen Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nusinersen Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nusinersen Sodium supplier is an individual or a company that provides Nusinersen Sodium active pharmaceutical ingredient (API) or Nusinersen Sodium finished formulations upon request. The Nusinersen Sodium suppliers may include Nusinersen Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Nusinersen Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Nusinersen Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Nusinersen Sodium active pharmaceutical ingredient (API) in detail. Different forms of Nusinersen Sodium DMFs exist exist since differing nations have different regulations, such as Nusinersen Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Nusinersen Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Nusinersen Sodium USDMF includes data on Nusinersen Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nusinersen Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Nusinersen Sodium suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nusinersen Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Nusinersen Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Nusinersen Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Nusinersen Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nusinersen Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Nusinersen Sodium suppliers with NDC on PharmaCompass.
Nusinersen Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nusinersen Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nusinersen Sodium GMP manufacturer or Nusinersen Sodium GMP API supplier for your needs.
A Nusinersen Sodium CoA (Certificate of Analysis) is a formal document that attests to Nusinersen Sodium's compliance with Nusinersen Sodium specifications and serves as a tool for batch-level quality control.
Nusinersen Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Nusinersen Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nusinersen Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Nusinersen Sodium EP), Nusinersen Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nusinersen Sodium USP).